Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Quest Diagnostics (DGX)

Quest Diagnostics Q4 revenue up 14.5%, EPS up 14.7%; 2025 outlook and dividend raised

Positive Impact 3 of 5 earnings Written later

Quest Diagnostics reported fourth quarter 2024 revenue of $2.62 billion, up 14.5%, and reported diluted EPS of $1.95, up 14.7%, with full year revenue of $9.87 billion, up 6.7%. The company gave 2025 reported diluted EPS guidance of $8.34 to $8.59 and raised its quarterly dividend 6.7% to $0.80 per share. Shareholders see higher reported earnings in 2024, a 2025 outlook above the 2024 reported EPS of $7.69, and a larger dividend.

Key points

  • Q4 2024 reported diluted EPS $1.95 vs. $1.70 in Q4 2023; adjusted diluted EPS $2.23, up 3.7%
  • Full year 2024 revenue $9.87 billion, up 6.7%; full year reported diluted EPS $7.69, up 2.7%
  • 2025 reported diluted EPS guidance $8.34 to $8.59; adjusted diluted EPS guidance $9.55 to $9.80
  • Quarterly dividend raised from $0.75 to $0.80 per share, payable April 21, 2025, record date April 7, 2025

The filing

CompanyQuest Diagnostics (DGX)
Form8-K, current report
Filed with the SECJan 30, 2025, 6:47 AM ET
Accession number0001022079-25-000008

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.